15:30 METFORMIN FOR TREATMENT OF ATYPICAL ANTIPSYCHOTIC-INDUCED WEIGHT GAIN AND ENDOCRINOLOGICAL SIDE EFFECTS IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA: RESULTS FROM RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY

2012 ◽  
Vol 136 ◽  
pp. S77
Author(s):  
Ren-Rong Wu ◽  
Hua Jin ◽  
Kenning Gao ◽  
Ping Shao ◽  
Philip K. Chan ◽  
...  
Keyword(s):  
Weight Gain ◽  
Side Effects ◽  
Atypical Antipsychotic ◽  
Controlled Study ◽  
First Episode ◽  
Double Blind ◽  
Double Blind Placebo ◽  
First Episode Schizophrenia

Olanzapine-Induced Weight Gain in Patients With First-Episode Schizophrenia: A Double-Blind, Placebo-Controlled Study of Fluoxetine Addition

2002 ◽  
Vol 159 (6) ◽  
pp. 1058-1060 ◽  
Author(s):  
Michael Poyurovsky ◽  
Artashes Pashinian ◽  
Irit Gil-Ad ◽  
Rachel Maayan ◽  
Michael Schneidman ◽  
...  
Keyword(s):  
Weight Gain ◽  
Controlled Study ◽  
First Episode ◽  
Double Blind ◽  
Double Blind Placebo ◽  
First Episode Schizophrenia

Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study

2014 ◽  
Vol 53 ◽  
pp. 133-140 ◽  
Author(s):  
Amirhossein Modabbernia ◽  
Parvaneh Heidari ◽  
Robabeh Soleimani ◽  
Abdolrasoul Sobhani ◽  
Zahra Atrkar Roshan ◽  
...  
Keyword(s):  
Side Effects ◽  
Controlled Study ◽  
First Episode ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Metabolic Side Effects ◽  
First Episode Schizophrenia

scholarly journals Dietary fiber and probiotics for the treatment of atypical antipsychotic-induced metabolic side effects: study protocol for a randomized, double-blind, placebo-controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Chenchen Liu ◽  
Dongyu Kang ◽  
Jingmei Xiao ◽  
Yuyan Huang ◽  
Xingjie Peng ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Weight Gain ◽  
Side Effects ◽  
Dietary Fiber ◽  
Atypical Antipsychotic ◽  
Double Blind ◽  
Antipsychotic Medications ◽  
Double Blind Placebo ◽  
Metabolic Side Effects ◽  
Atypical Antipsychotic Medications

Abstract Background Atypical antipsychotic medications, which are effective for the treatment of schizophrenia and bipolar disorder, are associated with features of metabolic syndrome, such as weight gain, hyperglycemia, dyslipidemia, and insulin resistance. Although there are a few studies on the effects of dietary fiber or probiotics on weight loss in obese people, no published trials have reported the efficacy of dietary fiber and probiotics on reducing atypical antipsychotic-induced weight gain. Methods For this 12-week randomized, double-blind, placebo-controlled study, 100 patients with a weight gain of more than 10% after taking atypical antipsychotic medications were recruited. Participants were randomized to four groups as follows: probiotics (840 mg twice daily (bid)) plus dietary fiber (30 g bid), probiotics (840 mg bid) plus placebo, placebo plus dietary fiber (30 g bid), or placebo group. The primary outcome was the change in body weight. Secondary outcomes included changes in metabolic syndrome parameters, appetite score, biomarkers associated with a change in weight, and gut microbiota composition and function. Discussion To date, this is the first randomized, placebo-controlled, double-blinded trial investigating the efficacy of dietary fiber and probiotics alone and in combination to reduce metabolic side effects induced by atypical antipsychotic medications. If effective, it is possible to conclude that dietary fiber and probiotics can reduce atypical antipsychotic-induced metabolic side effects. Trial registration number ClinicalTrials.gov NCT03379597. Registered on 19 November 2017.

scholarly journals Effects of Piracetam as an Adjuvant Therapy on Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 15 (2) ◽  
Author(s):  
Kaveh Alavi ◽  
Elham Shirazi ◽  
Maryam Akbari ◽  
Zahra Shahrivar ◽  
Fatemeh-Sadat Noori ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Placebo Group ◽  
Side Effects ◽  
Adjuvant Therapy ◽  
Attention Deficit ◽  
Controlled Study ◽  
Double Blind ◽  
Children With Adhd ◽  
Double Blind Placebo ◽  
Hyperactivity Disorder

Background: Stimulants are highly effective in controlling symptoms of Attention-deficit/hyperactivity disorder (ADHD), but 30% of individuals with ADHD do not respond to them or cannot tolerate their side effects; thus, alternative treatment approaches need to be considered. Objectives: To evaluate the effect and safety of piracetam as an adjuvant therapy plus methylphenidate (MPH) in children with ADHD. Methods: Thirty-six children with ADHD (6-16 years old), admitted to three academic outpatient child psychiatric clinics in the second half of 2015, were randomly assigned to the “methylphenidate plus piracetam group” and the “methylphenidate plus placebo” group, in a double-blind, placebo-controlled study, for 6 weeks. The “Conner’s Parents’ Rating Scale-Revised (CPRS-R), Children Symptom Inventory-4 (CSI-4), Clinical Global Impression-Improvement scale (CGI-I), and Children’ Global Assessment Scale (CGAS) were completed at baseline and at the ends of the third and the sixth week, and the New York State Psychiatric Institute side effect forms were completed weekly, as outcome measures. Results: The level of improvement in CPRS-R, CSI-4, and CGI-I scales were significantly higher in the “methylphenidate plus piracetam” group compared with the “methylphenidate plus placebo” group. Side effects were not remarkable in any group. Conclusions: Piracetam as a short-term adjuvant treatment to methylphenidate can have considerable therapeutic effect and safety profile in children with ADHD and deserves further exploration to assess its potentialities in ADHD treatment.

Sign in / Sign up

Export Citation Format

Share Document